IAPs: guardians of RIPK1.

Article Details


Darding M, Meier P

IAPs: guardians of RIPK1.

Cell Death Differ. 2012 Jan;19(1):58-66. doi: 10.1038/cdd.2011.163. Epub 2011 Nov 18.

PubMed ID
22095281 [ View in PubMed

Deregulation of innate immune signalling and cell death form the basis of most human disease pathogenesis. Inhibitor of APoptosis (IAP) protein-family members are frequently overexpressed in cancer and contribute to tumour cell survival, chemo-resistance, disease progression and poor prognosis. Although best known for their ability to regulate caspases, IAPs also influence ubiquitin-dependent pathways that modulate innate immune signalling by activation of NF-kappaB. Recent advances in our understanding of the molecular mechanisms through which IAPs influence cell death and innate immune responses have provided new insights into novel strategies for treatment of cancer. In this review we discuss our current understanding of IAP-mediated NF-kappaB signalling, as well as elaborate on unexpected insights into the involvement of IAPs in regulating the 'Ripoptosome', a novel intrinsic cell death-inducing platform. We propose an evolutionarily conserved concept whereby IAPs function as guardians of killer platforms such as the apoptosome in Drosophila and the Ripoptosome in mammals.

DrugBank Data that Cites this Article

NameUniProt ID
E3 ubiquitin-protein ligase XIAPP98170Details